A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

Inclusion Criteria: * Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy. * No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. * Life expectancy of at least 12 weeks. * Performance status equal to or less than Zubrod 2. * Signed informed consent. * Patients with measurable disease. * Age at least 16 years. * Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. * Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal. * Adequate renal function defined as serum creatine less than or equal to 1.5 mg %. Exclusion Criteria: * No serious intercurrent illness. * Adequate contraception (if applicable). * NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV. * NO experimental clinical trial within 3 weeks of study entry. * NO patients with active CNS disease. * Full recovery from any prior surgical treatment. * NO active active infections.